CRISPR Therapeutics (CRSP)
Develops genome-editing medicines across blood disorders, liver targets, autoimmune disease, and diabetes.
Something off on this page? Send us feedback.
Develops CRISPR-based medicines for blood disorders alongside in vivo editing, allogeneic CAR T, siRNA, and regenerative-medicine programs. CASGEVY is the approved commercial anchor; Vertex controls its global development, manufacturing, and commercialization under a profit-and-cost-sharing collaboration.
Develops gene-based medicines through CRISPR/Cas9 editing and related technologies. CASGEVY, an ex vivo edited-cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, is the approved commercial product and is partnered with Vertex.
The pipeline spans liver-directed in vivo editing through CTX310, CTX340, and CTX460; zugo-cel, an allogeneic CAR T candidate for autoimmune disease and blood cancers; CTX611, an siRNA candidate for clotting disorders; and CTX213, a beta-cell replacement candidate for diabetes. Lipid-nanoparticle delivery, SyNTase editing, and an internal cell-therapy manufacturing facility support these programs.
Operates as a single genome-editing therapeutics segment, with headquarters in Switzerland and research operations in the United States. Clinical progress depends on regulatory review, complex manufacturing, and intellectual-property rights. Vertex controls global development, manufacturing, and commercialization of CASGEVY under the collaboration agreement.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | Goldman Sachs | Reiterate | Rating: —Target: — | Target: $55 |
| Jul 8, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $65 | Target: $80 |
| Jun 12, 2026 | UBS | Target | Target: — | Target: $80 |
| Jun 11, 2026 | Morgan Stanley | Target | Target: $33 | Target: $60 |
| May 13, 2026 | Bernstein | Reiterate | Rating: —Target: — | Target: $56 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.36B · Total debt $783.7M · Total assets $2.65B · Shareholders' equity $1.75B
- Revenue
- $10.2M
- Operating income
- −$114.8M
- Net income
- −$91.2M
No dividends on record.
| Institutions | 80.04% | 77.40M shares | |
|---|---|---|---|
| 558 holders · as of Jun 30, 2026 | |||
| Insiders | 0.46% | 445.4K shares | |
| 9 holders · as of Sep 21, 2026 | |||
| Other | 19.50% | 18.85M shares | |
| remainder | |||
96.69M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ark Investment Management LLCInstitution | 9.78% | 9.46M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.63% | 8.35M | as of Jun 30, 2026 |
Orbis Investment Management LtdInstitution | 6.30% | 6.09M | filed May 15, 2026 |
Orbis Allan Gray LtdInstitution | 5.64% | 5.45M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 4.91% | 4.75M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Ali Behbahani | director | −13,679 | $57.09 |
| May 29, 2026 | Naimish Patel | officer: Chief Medical Officer | −3,786 | $55.62 |
| Mar 23, 2026 | Raju Prasad | officer: Chief Financial Officer | −3,708 | $46.78 |
| Mar 23, 2026 | Samarth Kulkarni | director, officer: Chief Executive Officer | −10,020 | $46.78 |
| Mar 23, 2026 | James R. Kasinger | officer: General Counsel and Secretary | −3,182 | $46.78 |
- Beam Therapeutics
Base-editing rival in SCD and liver genetic disease
- Intellia Therapeutics
Late-stage systemic CRISPR rival in in vivo editing
- Editas Medicine
CRISPR peer in hemoglobinopathy and in vivo editing
- Allogene Therapeutics
Off-the-shelf CAR T rival in oncology and autoimmunity
- Caribou Biosciences
CRISPR-edited allogeneic CAR T rival in blood cancers
- Fate
iPSC off-the-shelf CAR T rival in autoimmune disease
- Sana Biotechnology
Engineered islet-cell rival in regenerative medicine
- Prime Medicine
Prime-editing platform peer in liver and cell therapy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics | $58.26 | −1.30% | $5.69B | — | — | 425.1 | +1,041.4% |
| Beam Therapeutics | $25.47 | −1.77% | $2.67B | — | — | 17.1 | −94.2% |
| Intellia Therapeutics | $12.37 | −2.52% | $1.77B | — | — | 29.8 | −46.2% |
| Editas Medicine | $3.06 | +4.79% | $448.1M | — | — | 9.5 | +232.3% |
| Allogene Therapeutics | $1.70 | −0.88% | $590.2M | — | — | 127.2 | — |
| Caribou Biosciences | $1.31 | −1.89% | $132.9M | — | — | 13.2 | −43.8% |
| Fate | $2.56 | −0.97% | $300.7M | — | — | 46.3 | +9.2% |
| Sana Biotechnology | $3.17 | −4.95% | $926.7M | — | — | — | — |
| Prime Medicine | $3.47 | −2.12% | $639.4M | — | — | 157.0 | +3.5% |
| Median | — | — | 29.8 | −20.1% |